Aveeno is the oat brand — founded in the United States in 1945, named after Avena sativa, and met by an Indian shopper as an American pharmacy staple. Two things about the bottle sold here are worth knowing before you pay ₹1,640 for 354 millilitres of body lotion. It was filled in South Korea. And its owner is neither Johnson & Johnson nor, yet, Kimberly-Clark.
Aveeno belongs to Kenvue, the consumer-health company Johnson & Johnson separated in 2023. The Indian stock is made in South Korea, and the two lotions we could match sell here at ₹4.63 and ₹3.56 per millilitre at MRP against ₹2.13 and ₹1.79 at one American retailer on 4 September 2026. On 22 June 2026 the advertising council examined the brand’s 72-hour hydration claim and did not uphold the complaint.
Snapshot
- Founded
- 1945, United States; the name comes from Avena sativa, the oat
- Current owner
- Kenvue Inc., NYSE: KVUE — separated from Johnson & Johnson in 2023
- Indian company
- JNTL Consumer Health (India) Private Limited, CIN U24290MH2022FTC376097, Mulund (West), Mumbai
- Where the Indian stock is made
- South Korea — Johnson & Johnson Korea Ltd, on all three declarations read
- Indian range
- 12 products: body, baby and cleansing. No face serum, no acne line, no sunscreen
- Indian prices
- ₹306 to ₹1,440 at Apollo Pharmacy’s selling prices, 4 September 2026
- Advertising record
- One matter, 22 June 2026, not upheld
How it started
The brand dates to 1945 and takes its name from the oat, on its own heritage telling. Who sold the business to whom across the 1980s and 1990s we have not read from a primary record, so this audit prints no dates for it. The recent chain is documented, and most readers have it wrong: Johnson & Johnson listed its consumer arm as Kenvue in May 2023 and sold its last shares in May 2024. Kimberly-Clark signed a merger agreement with Kenvue on 2 November 2025, at an enterprise value of about $48.7 billion. Summaries saying that takeover happened in 2025 are ahead of the record.
- May 2023J&J lists Kenvue and begins the separation
- May 2024J&J sells its last Kenvue shares
- 2 Nov 2025Kimberly-Clark and Kenvue sign a merger agreement
- 29 Jan 2026Shareholders of both companies approve it
- 4 Sep 2026Kenvue’s newsroom carries no completion notice
Kenvue expects to close in the last quarter of 2026. On 4 September 2026 it had not.
What they actually make
Twelve products on the Indian site, across adult body and baby; Apollo Pharmacy lists 24 SKU-and-size combinations. Half the range is baby care. There is no serum, no acne line and no sunscreen here.
The manufacturer is the finding. We read three import declarations across two products and two platforms, and every one names Johnson & Johnson Korea Ltd as the maker. One, on the Skin Relief lotion, states “South Korea” as the country of origin in terms. Three declarations is a small sample and we print it as one, but it is unanimous.
An American brand from 1945, sold in India as American, filled in Korea.
Two details sit beside it. The Korean addresses differ — Cheongju on one declaration, Changwon on another — and we report both rather than pick one. And the importer is named two ways: the marketplace listing, live since October 2015 and predating the Kenvue separation, says “Johnson & Johnson Pvt Ltd”; the pharmacy listings and the advertising council’s record say “JNTL Consumer Health (India) Private Limited”. The older listing carries the older label.
- Johnson & Johnson Korea LtdManufacturer and packer on all three Indian declarations read
- JNTL Consumer Health (India) Private LimitedThe importer on the pharmacy listings, Mulund (West), Mumbai
- Pharmacy and beauty e-commerceMRP ₹1,640 for 354 ml; sold at ₹1,361.20 to ₹1,476 on 4 September 2026
Kenvue’s India page says the company owns two Indian plants, at Mumbai and Baddi. Neither Aveeno product we traced is made at either — an imported brand sold by an Indian company that does own factories, which is the marketer-versus-manufacturer question our Campus audit works from the other end.
The oat is the most interesting thing on the label, and the interest is regulatory. In America colloidal oatmeal is a permitted skin-protectant active under the FDA monograph at 21 CFR Part 347, with a floor of 0.007 per cent. That makes an American oat lotion a drug in law: Drug Facts panel, declared active, declared strength. Aveeno’s American eczema creams are filed on that basis by Kenvue Brands LLC, declaring “Colloidal oatmeal 1%” on one and 2 per cent on another.
India regulates the same products as cosmetics under the Cosmetics Rules 2020. On the Indian packs the oat sits in the ingredient list as “Avena Sativa (Oat) Kernel Flour” with no percentage and no drug status — eighth of eleven ingredients in the Daily Moisturizing Lotion, eighth of fourteen in Skin Relief, fourth of fifteen in Baby Dermexa. The word “colloidal” appears in the Indian marketing copy and in no ingredient list we read, while the Baby Dermexa page claims relief for “eczema-prone skin”.
That is a disclosure observation about two labelling systems, not a finding about the product. Ingredient order gives a ranking, not a number, and no Indian strength is published, so no comparison of strength is possible either way. This audit is not medical advice and recommends nothing for a skin condition.
What Aveeno costs in India
Everything below was checked on 4 September 2026. The Indian figures are MRP and Apollo Pharmacy’s selling price; the American figure is one retailer’s shelf price the same day, because the United States has no MRP. That Skin Relief price was promotional. Conversion at ₹95.38 to the dollar, the Federal Reserve’s rate released 31 August 2026.
- Skin Relief lotion, one US retail price
- ₹2.13 per ml
- Same lotion, Indian MRP
- ₹4.63 per ml
- Gap
- +116%
- Checked on
- 4 September 2026
| Product | India, ₹/ml at MRP | One US retail price, ₹/ml |
|---|---|---|
| Skin Relief lotion, 354 ml here, 12 fl oz there | ₹4.63 | ₹2.13 |
| Daily Moisturizing lotion, 354 ml here, 18 fl oz there | ₹3.56 | ₹1.79 |
At MRP that is 216 and 199 per cent of the American shelf; at Apollo’s actual selling price it narrows to 181 and 163 per cent. Only the first row is size for size — the American Daily Moisturizing bottle is half again as large, which flatters it per millilitre. Both land near double either way.
This is where Aveeno runs against the pattern. Among the imported dermatology brands we priced the same week, the ones brought in by their owner’s own Indian subsidiary sold below their home-market list price — Bioderma at 51 per cent of its French list, Eucerin at 65 per cent of its German one, La Roche-Posay at 69 per cent. Brands arriving through a third party ran dearer. Aveeno has an owner’s-own importer and sells at roughly twice one American price.
That is not a contradiction of the pattern. The Indian bottle was filled in South Korea, so the American shelf is the wrong comparator — this stock never passes through the American price structure. An American supermarket price against an Indian pharmacy MRP also compares channels as much as countries.
The Indian bottles are filled in South Korea, so the American shelf is not the market this stock comes from, and we have no Korean price for the matching sizes. Read the doubling as what you pay here, not as proof of an Indian mark-up.
The more useful arithmetic is inside the Indian range. On most brands the big pack is cheaper per unit. On three Aveeno lines it is dearer.
| Product | Smaller pack | Larger pack |
|---|---|---|
| Baby Soothing Relief Moisture Cream | ₹4.82/g at 140 g | ₹5.73/g at 227 g |
| Baby Dermexa Moisturising Cream | ₹8.00/g at 100 g | ₹8.74/g at 206 g |
| Baby Daily Moisture Wash & Shampoo | ₹2.68/ml at 354 ml | ₹2.73/ml at 532 ml |
| Skin Relief Moisturizing Lotion | ₹7.03/ml at 71 ml | ₹4.63/ml at 354 ml |
MRP per unit, Apollo Pharmacy brand page, 4 September 2026.
The bigger tub of Baby Soothing Relief costs 19 per cent more per gram than the smaller one, Baby Dermexa’s larger jar 9 per cent more; the Skin Relief lotion runs the ordinary way round, its small tube 52 per cent dearer per millilitre. There is no rule, so the sum has to be done line by line.
Prices move between sellers on the same day too: the Skin Relief 354 ml was ₹1,361.20 at one pharmacy and ₹1,476 at another on 4 September 2026, against an MRP of ₹1,640. That gap between printed maximum and price charged is what our Metro audit tracks on footwear.
Who Aveeno is actually for
Aveeno in India is a body and baby brand, not a face brand, so the questions that dominate the rest of this shelf — filter systems, SPF substantiation, percentages on a dropper bottle — do not arise. What you buy is a large bottle of fragrance-free lotion built on oat, petrolatum and glycerin.
That suits someone who wants a plain unscented body moisturiser and will pay a premium for a trusted name, and a parent buying baby cream on the same strength. It does not suit anyone shopping on cost per millilitre. Where the brand argues its case well is the exclusion list: Baby Dermexa’s page says the product is made without parabens, phthalates, fragrances, dyes or phenoxyethanol, and the ingredient list on the same page bears that out. That is what a free-from claim looks like when it names what it leaves out.
Reputation and controversies
The single entry on Aveeno’s Indian advertising record is a clearance, and it deserves stating plainly. On 22 June 2026 the Advertising Standards Council of India examined a claim on the Skin Relief lotion’s Indian website — “This fragrance-free lotion provides clinically proven long-lasting intense hydration for 72 hours*, relief dry, itchy skin in 20 seconds” — and held that the claim was not in contravention of Chapter I of its code. Case 2606-CCC.07. The council raised the matter itself through its own advertisement monitoring, rather than acting on a rival or a member of the public.
Chapter I is the truthful-representation chapter, the same one under which the council has upheld complaints about clinical and dermatologist language against other brands on this shelf. Aveeno’s clinical claim went to that test and stood. The matter concerns a product claim; there is no influencer or disclosure matter on the record.
Two limits belong with it, and neither takes it away. The council is the advertising industry’s self-regulatory body rather than a statutory regulator, and what it examined was one advertisement as it stood in June 2026 — one claim, one product, one website. It says nothing about the 48-hour claim on the Daily Moisturizing Lotion or the eczema-prone-skin claim on Baby Dermexa, and nobody has examined the pages as they read today. Within those limits it is a decided outcome in the brand’s favour, and the only product-claim clearance among the dermatology brands we checked that week.
What the brand publishes behind its own numbers is a separate question. Aveeno’s Indian pages carry “30+ Clinical Studies” and “3000+ Patients Studied”, and no study title, journal, date or sample description appears on any Aveeno page we read on 4 September 2026. The 48-hour claim carries an asterisk that, on the page as read that day, resolved to no visible footnote. A regulator being satisfied and a reader seeing the study are two different things.
The Baby Dermexa page says “Brand recommended by US Pediatricians and Dermatologists”. The scope is stated on the page — American doctors — so it is not a claim of Indian endorsement and should not be read as one. No survey, sample or year is given for it.
On animal testing the record is stale rather than adverse. PETA’s Beauty Without Bunnies directory carries an entry filed as “Aveeno (Johnson & Johnson)” saying the company does test on animals; it was last modified on 18 June 2020, three years before Johnson & Johnson separated the business as Kenvue, so it names a parent that no longer owns the brand. Kenvue publishes no animal-testing policy we could find, so this audit calls Aveeno neither cruelty-free nor otherwise.
No Indian court decision concerning Aveeno appears in the judgment databases as at 4 September 2026. Those do not index every consumer forum, so read that as nothing found rather than nothing there.
Buying it in India
Read the manufacturer line on the back
It names the maker and, where printed, the country of origin. On the Aveeno stock we traced, that line names a Korean company, and one listing says South Korea outright.
Ask the seller for the import registration number
Imported cosmetics need registration with the central drug authority under the Cosmetics Rules 2020, and the certificate sits with the Indian importer. The register cannot be looked up from outside, so the number has to come from the seller. No Aveeno listing we read printed one; Avène’s Indian pack prints RC/COS-003873.
Do the per-millilitre sum before you upsize
On three Aveeno lines the larger pack costs more per gram or millilitre. Divide price by the net quantity printed on the pack, every time.
Compare the MRP against two pharmacies
The 354 ml Skin Relief lotion carries an MRP of ₹1,640 and sold at ₹1,361.20 and ₹1,476 on the same day. The printed maximum is not the price.
Look for a number next to the oat
The Indian ingredient list names oat flour, oil and extract without a strength. If a percentage matters to you, it is not on the Indian pack.
We found no Indian seizure, alert or enforcement outcome concerning Aveeno, so this audit reports none. Buy where the seller will show you the import declaration, and treat a price far below the ₹1,300-odd pharmacies charge for the 354 ml lotion as a reason to ask questions — the test our Bata audit applies to a brand whose name and whose Indian company are different things.
Common questions
Is Aveeno sold in India made in America?
Not on the evidence we read. Three import declarations across two products and two platforms all name Johnson & Johnson Korea Ltd as the manufacturer, and one states South Korea as the country of origin. The brand is American in origin; the Indian stock is Korean-made.
Who owns Aveeno now?
Kenvue Inc., the consumer-health company Johnson & Johnson listed in May 2023 and fully exited in May 2024. Kimberly-Clark signed an agreement to buy Kenvue on 2 November 2025 and shareholders approved it on 29 January 2026, but as at 4 September 2026 the deal had not closed. In India the brand is sold by JNTL Consumer Health (India) Private Limited.
Why is Aveeno dearer in India than in America?
At MRP the two matching lotions run at 199 to 216 per cent of one American retailer’s shelf price per millilitre. The Indian stock is Korean-made, so the American shelf is not the market it comes from, and an American supermarket price is a different kind of price from an Indian pharmacy MRP. We have no Korean price to compare against.
Has the advertising council ruled against Aveeno?
The opposite. On 22 June 2026 it examined the “clinically proven… 72 hours” claim on the Skin Relief lotion’s website and did not uphold the complaint. That covers one claim on one product as the advertisement then stood, and the council is a self-regulatory body rather than a statutory regulator.
Is Indian Aveeno the same as American Aveeno?
The labelling is not. In America the eczema creams are over-the-counter drugs with a Drug Facts panel declaring 1 or 2 per cent colloidal oatmeal. In India the same oat is an ordinary cosmetic ingredient with no percentage, because India regulates these products as cosmetics. Whether the formulations otherwise match is not something either label lets you establish.
How we research and verify brand audits: our methodology.
References
- Aveeno India, 4 September 2026 — the Indian range and publisher
- Aveeno India, Skin Relief Moisturizing Lotion, 4 September 2026 — the 72-hour claim
- Aveeno India, Daily Moisturizing Lotion, 4 September 2026 — the 48-hour claim and its asterisk
- Aveeno India, Baby Dermexa Moisturising Cream, 4 September 2026 — the eczema, US-doctor and free-from claims, and the ingredient list
- Kenvue Inc. Form 10-K for FY2025, filed 20 February 2026 — the separation and the merger agreement date
- Kenvue newsroom, 4 September 2026 — no completion notice
- Kenvue second-quarter 2026 results, 6 August 2026 — the expected close
- Kenvue India locations, 4 September 2026 — the Mumbai and Baddi plants
- Tata 1mg, Skin Relief Moisturizing Lotion 354 ml, 4 September 2026 — the South Korea declaration and one selling price
- Tata 1mg, Daily Moisturising Lotion 354 ml, 4 September 2026 — the second Korean declaration
- Amazon India, Skin Relief Moisturizing Lotion 354 ml, 4 September 2026 — the third declaration and the older importer name
- Apollo Pharmacy, Aveeno brand page, 4 September 2026 — every Indian MRP and selling price above
- Walmart, Skin Relief Moisturizing Lotion 12 fl oz, 4 September 2026 — the American price used, promotional on the day
- Walmart, Daily Moisturizing Body Lotion 18 fl oz, 4 September 2026 — the second American price
- Federal Reserve H.10 release, 31 August 2026 — the ₹95.38 to the dollar
- 21 CFR Part 347, skin protectant drug products, 4 September 2026 — colloidal oatmeal as a permitted active
- DailyMed, Aveeno labels filed by Kenvue Brands LLC, 4 September 2026 — the 1 and 2 per cent declarations
- Advertising Standards Council of India, complaint outcomes, 4 September 2026 — case 2606-CCC.07, not upheld
- PETA Beauty Without Bunnies, Aveeno (Johnson & Johnson), last modified 18 June 2020 — the entry and its date
- CDSCO, registration and import of cosmetics, 19 January 2021 — the registration requirement
Aveeno comes out of this better than most of the dermatology shelf on the thing this site cares about most: its clinical claim was tested by the advertising council on 22 June 2026 and it stood. That is a real result, and rarer than the marketing on any of these bottles. The exclusion list on Baby Dermexa is honest work too — it names what is left out, and the ingredient list matches.
The price is the problem. ₹4.63 a millilitre at MRP for a bottle filled in South Korea, against ₹2.13 on one American shelf, is a lot for a lotion of oat, petrolatum and glycerin — and the brand prints a study count with no study behind it. The one number nobody gives you is the strength of the oat, which America requires on the panel and India does not.
A brand that passed the one test a regulator set it, at a price that assumes you will not divide by the net quantity — and on three of its own lines, the bigger tub costs more per gram.
